Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 10, 2001, Pages 1667-1672

  Hasegawa, T ^a   Yoneda, M ^a,b   Nakamura, K ^a   Makino, I ^a   Terano, A ^b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; FEMALE; HUMAN; LIVER BIOPSY; MALE; NON ALCOHOLIC STEATOHEPATITIS; PATIENT SELECTION; PRIORITY JOURNAL;

ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ALPHA-TOCOPHEROL; ASPARTATE AMINOTRANSFERASES; BODY WEIGHT; CHOLESTEROL; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS; HUMANS; LIVER CIRRHOSIS; MALE; PILOT PROJECTS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRIGLYCERIDES;

EID: 0034799895     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01083.x     Document Type: Article

References (31)

1. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease
2. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
3. Nonalcoholic steatohepatitis: An expanded clinical entity
4. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients
5. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases
6. Nonalcoholic steatohepatitis and the 'bright liver syndrome': Should a recently expanded clinical entity be further expanded?
7. Nonalcoholic steatohepatitis
8. Nonalcoholic steatohepatitis
9. Effect of weight reduction on hepatic abnormalities in overweight patients
10. Hepatic effects of dietary weight loss in morbidly obese subjects
11. In vitro and in vivo association of transforming growth factor-β1 with hepatic fibrosis
12. Type I procollagen production and cell proliferation is mediated by transforming growth factor-β in a model of hepatic fibrosis
13. Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions
14. Lipid peroxidation stimulated by carbon tetrachloride or iron and hepatocyte death: Protective effect of vitamin E
15. Vitamin E dietary supplementation inhibits transforming growth factor β1 gene expression in the rat liver
16. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis
17. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
18. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
19. Sandwich enzyme-linked immunosorbent assays (SELISAs) quantitate and distinguish two forms of transforming growth factor-β (TGF-β1 and TGF-β2) in complex biological fluids
20. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1
21. Transforming growth factor-β (TGF-β) isoforms in rat liver regeneration: Messenger RNA expression and activation of latent TGF-β
22. Transforming growth factor-β gene expression in normal and fibrotic rat liver
23. Transforming growth factor-β1 in chronic hepatitis C
24. Immunohistochemical detection of transforming growth factor-β1 in fibrotic liver diseases
25. Increased transforming growth factor-β1 gene expression in human liver disease
26. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor β: Implication for a pathogenetic role in alcoholic liver fibrogenesis
27. The transforming growth factor-β family
28. Prognostic value of MIP-1α, TGF-β2, sELAM-1, and sVCAM-1 in patients with gram-positive sepsis
29. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?
30. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis
31. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study